Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for Adlarity (donepezil transdermal system) for the Treatment of Alzheimer ’s Disease

MENLO PARK, Calif., January 27, 2020 (GLOBE NEWSWIRE)– Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news